{"id":46617,"date":"2021-01-11T11:53:50","date_gmt":"2021-01-11T11:53:50","guid":{"rendered":"https:\/\/parkinson.ca\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/"},"modified":"2025-01-17T23:08:12","modified_gmt":"2025-01-17T23:08:12","slug":"bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson","status":"publish","type":"post","link":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/","title":{"rendered":"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l&rsquo;autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson."},"content":{"rendered":"<p>BlueRock Therapeutics a diffus\u00e9 un communiqu\u00e9 de presse le 7 janvier 2020 annon\u00e7ant le financement d&rsquo;un essai de deux ans utilisant des cellules souches de donneurs adultes. L&rsquo;avis de Parkinson Canada : Cette nouvelle est un \u00a0\u00bb d\u00e9veloppement important en Am\u00e9rique du Nord, car la FDA des \u00c9tats-Unis approuve le premier essai visant \u00e0 \u00e9tudier l&rsquo;utilisation de neurones dopaminergiques d\u00e9riv\u00e9s de cellules souches pluripotentes chez des patients atteints de la maladie de Parkinson \u00ab\u00a0. Le syst\u00e8me utilise des cellules de donneurs adultes comme mat\u00e9riau de d\u00e9part et les reprogramme en neurones dopaminergiques qui sont transplant\u00e9s dans la r\u00e9gion du cerveau affect\u00e9e par la maladie de Parkinson. \u00c0 New York, l&rsquo;essai clinique de phase I, d&rsquo;une dur\u00e9e de deux ans, portera sur 10 patients et se concentrera sur l&rsquo;examen de la s\u00e9curit\u00e9 et de la tol\u00e9rabilit\u00e9 de la greffe.\u00a0\u00bb Lisez l <a href=\"https:\/\/bluerocktx.com\/news\/bluerock-therapeutics-in-collaboration-with-memorial-sloan-kettering-cancer-center-receives-ind-clearance-for-da01-in-parkinsons-disease\/\">&lsquo;article complet<\/a> dans <a href=\"https:\/\/bluerocktx.com\/news\/bluerock-therapeutics-in-collaboration-with-memorial-sloan-kettering-cancer-center-receives-ind-clearance-for-da01-in-parkinsons-disease\/\">son<\/a> contexte.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BlueRock Therapeutics a diffus\u00e9 un communiqu\u00e9 de presse le 7 janvier 2020 annon\u00e7ant le financement d&rsquo;un essai de deux ans utilisant des cellules souches de donneurs adultes. L&rsquo;avis de Parkinson Canada : Cette nouvelle est un \u00a0\u00bb d\u00e9veloppement important en Am\u00e9rique du Nord, car la FDA des \u00c9tats-Unis approuve le premier essai visant \u00e0 \u00e9tudier [&hellip;]<\/p>\n","protected":false},"author":107,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[64],"tags":[],"audience":[],"class_list":["post-46617","post","type-post","status-publish","format-standard","hentry","category-actualites"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"BlueRock Therapeutics a diffus\u00e9 un communiqu\u00e9 de presse le 7 janvier 2020 annon\u00e7ant le financement d&#039;un essai de deux ans utilisant des cellules souches de donneurs adultes. L&#039;avis de Parkinson Canada : Cette nouvelle est un &quot; d\u00e9veloppement important en Am\u00e9rique du Nord, car la FDA des \u00c9tats-Unis approuve le premier essai visant \u00e0 \u00e9tudier\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"It Team Parkinson Canada\"\/>\n\t<meta name=\"google-site-verification\" content=\"2AhivUiST2eKQcfei6JBM5Zbf8YQRvHy0kRBp9sDLWo\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Parkinson Canada -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l\u2019autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson. - Parkinson Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"BlueRock Therapeutics a diffus\u00e9 un communiqu\u00e9 de presse le 7 janvier 2020 annon\u00e7ant le financement d&#039;un essai de deux ans utilisant des cellules souches de donneurs adultes. L&#039;avis de Parkinson Canada : Cette nouvelle est un &quot; d\u00e9veloppement important en Am\u00e9rique du Nord, car la FDA des \u00c9tats-Unis approuve le premier essai visant \u00e0 \u00e9tudier\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2021-01-11T11:53:50+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-01-17T23:08:12+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:title\" content=\"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l\u2019autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson. - Parkinson Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"BlueRock Therapeutics a diffus\u00e9 un communiqu\u00e9 de presse le 7 janvier 2020 annon\u00e7ant le financement d&#039;un essai de deux ans utilisant des cellules souches de donneurs adultes. L&#039;avis de Parkinson Canada : Cette nouvelle est un &quot; d\u00e9veloppement important en Am\u00e9rique du Nord, car la FDA des \u00c9tats-Unis approuve le premier essai visant \u00e0 \u00e9tudier\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#blogposting\",\"name\":\"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\\u00e7oit l\\u2019autorisation de mise sur le march\\u00e9 de DA01 dans le traitement de la maladie de Parkinson. - Parkinson Canada\",\"headline\":\"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\\u00e7oit l&rsquo;autorisation de mise sur le march\\u00e9 de DA01 dans le traitement de la maladie de Parkinson.\",\"author\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/itadminparkinson-ca\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/parkinson.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Parkinson-Canada-logo-23-RGB.jpg\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2021-01-11T11:53:50+00:00\",\"dateModified\":\"2025-01-17T23:08:12+00:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s, Not needed\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/actualites\\\/#listItem\",\"name\":\"Actualit\\u00e9s\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/actualites\\\/#listItem\",\"position\":2,\"name\":\"Actualit\\u00e9s\",\"item\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/actualites\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#listItem\",\"name\":\"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\\u00e7oit l&rsquo;autorisation de mise sur le march\\u00e9 de DA01 dans le traitement de la maladie de Parkinson.\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#listItem\",\"position\":3,\"name\":\"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\\u00e7oit l&rsquo;autorisation de mise sur le march\\u00e9 de DA01 dans le traitement de la maladie de Parkinson.\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/actualites\\\/#listItem\",\"name\":\"Actualit\\u00e9s\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\",\"name\":\"Parkinson Canada\",\"description\":\"Parkinson Canada empowers people living with Parkinson\\u2019s and their care partners to thrive. Through advocacy, education, and support, we work to improve access to care, advance research, and build a stronger Parkinson\\u2019s community across Canada. Join us in making a difference.\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"email\":\"info@parkinson.ca\",\"telephone\":\"+18005653000\",\"foundingDate\":\"1965-04-11\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":50,\"maxValue\":100},\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/parkinson.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Parkinson-Canada-logo-23-RGB.jpg\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/parkinsoncanada\",\"https:\\\/\\\/twitter.com\\\/parkinsoncanada\",\"https:\\\/\\\/instagram.com\\\/parkinsoncanada\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm_sAjRqhAaiutx2B9dOqng\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/parkinson-canada\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/itadminparkinson-ca\\\/#author\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/itadminparkinson-ca\\\/\",\"name\":\"It Team Parkinson Canada\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d7ff38347e6680b59c95e274bac730ec5be321d544bf2a1a8d8598a11007f722?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"It Team Parkinson Canada\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#webpage\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/\",\"name\":\"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\\u00e7oit l\\u2019autorisation de mise sur le march\\u00e9 de DA01 dans le traitement de la maladie de Parkinson. - Parkinson Canada\",\"description\":\"BlueRock Therapeutics a diffus\\u00e9 un communiqu\\u00e9 de presse le 7 janvier 2020 annon\\u00e7ant le financement d'un essai de deux ans utilisant des cellules souches de donneurs adultes. L'avis de Parkinson Canada : Cette nouvelle est un \\\" d\\u00e9veloppement important en Am\\u00e9rique du Nord, car la FDA des \\u00c9tats-Unis approuve le premier essai visant \\u00e0 \\u00e9tudier\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/itadminparkinson-ca\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/itadminparkinson-ca\\\/#author\"},\"datePublished\":\"2021-01-11T11:53:50+00:00\",\"dateModified\":\"2025-01-17T23:08:12+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"name\":\"Parkinson Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l\u2019autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson. - Parkinson Canada","description":"BlueRock Therapeutics a diffus\u00e9 un communiqu\u00e9 de presse le 7 janvier 2020 annon\u00e7ant le financement d'un essai de deux ans utilisant des cellules souches de donneurs adultes. L'avis de Parkinson Canada : Cette nouvelle est un \" d\u00e9veloppement important en Am\u00e9rique du Nord, car la FDA des \u00c9tats-Unis approuve le premier essai visant \u00e0 \u00e9tudier","canonical_url":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"2AhivUiST2eKQcfei6JBM5Zbf8YQRvHy0kRBp9sDLWo","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#blogposting","name":"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l\u2019autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson. - Parkinson Canada","headline":"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l&rsquo;autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson.","author":{"@id":"https:\/\/www.parkinson.ca\/fr\/author\/itadminparkinson-ca\/#author"},"publisher":{"@id":"https:\/\/www.parkinson.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/parkinson.ca\/wp-content\/uploads\/2025\/01\/Parkinson-Canada-logo-23-RGB.jpg","@id":"https:\/\/www.parkinson.ca\/fr\/#articleImage"},"datePublished":"2021-01-11T11:53:50+00:00","dateModified":"2025-01-17T23:08:12+00:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#webpage"},"isPartOf":{"@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#webpage"},"articleSection":"Actualit\u00e9s, Not needed"},{"@type":"BreadcrumbList","@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/#listItem","position":1,"name":"Home","item":"https:\/\/www.parkinson.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/#listItem","name":"Actualit\u00e9s"}},{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/#listItem","position":2,"name":"Actualit\u00e9s","item":"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#listItem","name":"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l&rsquo;autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson."},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#listItem","position":3,"name":"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l&rsquo;autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson.","previousItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/#listItem","name":"Actualit\u00e9s"}}]},{"@type":"Organization","@id":"https:\/\/www.parkinson.ca\/fr\/#organization","name":"Parkinson Canada","description":"Parkinson Canada empowers people living with Parkinson\u2019s and their care partners to thrive. Through advocacy, education, and support, we work to improve access to care, advance research, and build a stronger Parkinson\u2019s community across Canada. Join us in making a difference.","url":"https:\/\/www.parkinson.ca\/fr\/","email":"info@parkinson.ca","telephone":"+18005653000","foundingDate":"1965-04-11","numberOfEmployees":{"@type":"QuantitativeValue","minValue":50,"maxValue":100},"logo":{"@type":"ImageObject","url":"https:\/\/parkinson.ca\/wp-content\/uploads\/2025\/01\/Parkinson-Canada-logo-23-RGB.jpg","@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#organizationLogo"},"image":{"@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#organizationLogo"},"sameAs":["https:\/\/facebook.com\/parkinsoncanada","https:\/\/twitter.com\/parkinsoncanada","https:\/\/instagram.com\/parkinsoncanada","https:\/\/www.youtube.com\/channel\/UCm_sAjRqhAaiutx2B9dOqng","https:\/\/www.linkedin.com\/company\/parkinson-canada"]},{"@type":"Person","@id":"https:\/\/www.parkinson.ca\/fr\/author\/itadminparkinson-ca\/#author","url":"https:\/\/www.parkinson.ca\/fr\/author\/itadminparkinson-ca\/","name":"It Team Parkinson Canada","image":{"@type":"ImageObject","@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/d7ff38347e6680b59c95e274bac730ec5be321d544bf2a1a8d8598a11007f722?s=96&d=mm&r=g","width":96,"height":96,"caption":"It Team Parkinson Canada"}},{"@type":"WebPage","@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#webpage","url":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/","name":"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l\u2019autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson. - Parkinson Canada","description":"BlueRock Therapeutics a diffus\u00e9 un communiqu\u00e9 de presse le 7 janvier 2020 annon\u00e7ant le financement d'un essai de deux ans utilisant des cellules souches de donneurs adultes. L'avis de Parkinson Canada : Cette nouvelle est un \" d\u00e9veloppement important en Am\u00e9rique du Nord, car la FDA des \u00c9tats-Unis approuve le premier essai visant \u00e0 \u00e9tudier","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/www.parkinson.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/#breadcrumblist"},"author":{"@id":"https:\/\/www.parkinson.ca\/fr\/author\/itadminparkinson-ca\/#author"},"creator":{"@id":"https:\/\/www.parkinson.ca\/fr\/author\/itadminparkinson-ca\/#author"},"datePublished":"2021-01-11T11:53:50+00:00","dateModified":"2025-01-17T23:08:12+00:00"},{"@type":"WebSite","@id":"https:\/\/www.parkinson.ca\/fr\/#website","url":"https:\/\/www.parkinson.ca\/fr\/","name":"Parkinson Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/www.parkinson.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"Parkinson Canada -","og:type":"article","og:title":"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l\u2019autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson. - Parkinson Canada","og:description":"BlueRock Therapeutics a diffus\u00e9 un communiqu\u00e9 de presse le 7 janvier 2020 annon\u00e7ant le financement d'un essai de deux ans utilisant des cellules souches de donneurs adultes. L'avis de Parkinson Canada : Cette nouvelle est un &quot; d\u00e9veloppement important en Am\u00e9rique du Nord, car la FDA des \u00c9tats-Unis approuve le premier essai visant \u00e0 \u00e9tudier","og:url":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/","og:image":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png","og:image:secure_url":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png","og:image:width":1000,"og:image:height":600,"article:published_time":"2021-01-11T11:53:50+00:00","article:modified_time":"2025-01-17T23:08:12+00:00","article:publisher":"https:\/\/facebook.com\/parkinsoncanada","twitter:card":"summary_large_image","twitter:site":"@parkinsoncanada","twitter:title":"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l\u2019autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson. - Parkinson Canada","twitter:description":"BlueRock Therapeutics a diffus\u00e9 un communiqu\u00e9 de presse le 7 janvier 2020 annon\u00e7ant le financement d'un essai de deux ans utilisant des cellules souches de donneurs adultes. L'avis de Parkinson Canada : Cette nouvelle est un &quot; d\u00e9veloppement important en Am\u00e9rique du Nord, car la FDA des \u00c9tats-Unis approuve le premier essai visant \u00e0 \u00e9tudier","twitter:creator":"@parkinsoncanada","twitter:image":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png"},"aioseo_meta_data":{"post_id":"46617","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2025-01-28 11:25:15","updated":"2025-06-07 10:42:24","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.parkinson.ca\/fr\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/\" title=\"Actualit\u00e9s\">Actualit\u00e9s<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tBlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l\u2019autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson.\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.parkinson.ca\/fr\/"},{"label":"Actualit\u00e9s","link":"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/"},{"label":"BlueRock Therapeutics, en collaboration avec le Memorial Sloan Kettering Cancer Center, re\u00e7oit l&rsquo;autorisation de mise sur le march\u00e9 de DA01 dans le traitement de la maladie de Parkinson.","link":"https:\/\/www.parkinson.ca\/fr\/bluerock-therapeutics-en-collaboration-avec-le-memorial-sloan-kettering-cancer-center-recoit-lautorisation-de-mise-sur-le-marche-de-da01-dans-le-traitement-de-la-maladie-de-parkinson\/"}],"_links":{"self":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/posts\/46617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/users\/107"}],"replies":[{"embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/comments?post=46617"}],"version-history":[{"count":0,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/posts\/46617\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/media?parent=46617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/categories?post=46617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/tags?post=46617"},{"taxonomy":"audience","embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/audience?post=46617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}